Roles of the systemic inflammatory response biomarkers in the diagnosis of cancer patients with solid tumors by Yis, Ozgur Mehmet et al.
  
    
Exp Biomed Res 2019; 2(1):37-43                                                DOI: 10.30714/j-ebr.2019147582                                                        
                                                                                                                            
     
                             Research article 
  
Roles of the systemic inflammatory response biomarkers in the diagnosis of cancer 
patients with solid tumors 
 
Ozgur Mehmet Yis1, Guler Bugdayci1, Mine Busra Pehlivan1, Merve Basol2 
1Department of Biochemistry, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu, Turkey 
2Department of Biostatistics, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu, Turkey 
 
A BST R AC T   
 
Aim: Cancer is still considered as one of the leading causes of mortality worldwide. Various tumor 
factors have been used for the diagnosis and follow-up of solid tumors; however, their clinical features 
remains controversial in terms of their diagnostic, prognostic, and predictive values. In this study, we 
aimed to investigate the use of the systemic inflammatory response biomarkers, including the 
neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-
monocyte ratio (LMR), in the diagnosis of solid tumors.  
Method: We retrospectively analyzed the records of 256 patients with solid tumors, including lung, 
breast, liver, and pancreatic cancers, who were diagnosed at the outpatient clinics of our institution 
between January 2017 and July 2018. The neutrophil, lymphocyte, monocyte, and platelet counts 
were measured using a hematology analyzer and the results were analyzed statistically. 
Results: The results of the receiver operating characteristic analysis showed that the NLR and LMR 
could be statistically reliable biomarkers, with area under the curve (AUC) values of 0.574 (p = 0.017) 
and 0.596 (p = 0.002). However, the PLR statistically failed to discriminate the patients and the 
control subjects, with AUC values of 0.545 (p = 0.148).  
Conclusions: Certain systemic inflammatory response biomarkers, such as the NLR and LMR, can 
play roles in the clinical diagnosis of patients with solid tumors. 
Keywords: Solid tumors; systemic inflammatory response; diagnosis, neutrophil-to-lymphocyte 
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Introduction 
One of the highest worldwide mortality rate is 
still caused by cancer, which is estimated to be 
responsible for approximately  9.6 million 
deaths in 2018 [1]. Moreover, recent evidence 
shows that one in three people will develop 
cancer in their lifetimes, and among them, one 
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in four will die from it [2]. Globally, the most 
common cause of cancer-related death is 
resulted from lung cancer that is followed by 
lung, breast, liver, and pancreatic cancers, 
which account for approximately one half of 
all new cases and deaths [1,3–5].  
Various tumor biomarkers have been used in 
the diagnosis and follow-up of solid tumors, 
including the carcinoembryonic antigen, 
carbohydrate antigen 125 (CA 125), CA 19-9, 
α-fetoprotein, and tumor-specific growth 
factor. However, their clinical usefulness is 
controversial in terms of their diagnostic, 
prognostic, and predictive values [6–9]. In the 
literature, it has been explicitly showed that 
carcinogenesis and tumor growth are directly 
linked with  chronic inflammation and the 
host’s immune system response [10]. A direct 
correlation has been shown between systemic 
inflammation and poor outcomes in many 
types of solid tumors. However, inflammation 
has been linked to both the development and 
progression of cancer [11]. Tumor-associated 
neutrophils, macrophages, and platelets found 
in the tumor microenvironment is responsible 
for the growth of tumors and the spread of 
metastases, leading to poor outcomes in a 
variety of malignancies [3,12–14]. The 
biochemical and hematological biomarkers, 
such as an elevated C-reactive protein 
concentration and increased white blood cell, 
neutrophil, and platelet counts are the most 
commonly preferred methods for the clinical 
measure of systemic inflammatory response in 
cancer patients [15]. The peripheral blood-
based parameters have been evaluated as 
factors that might be linked to a host’s immune 
response. The results has suggested that an 
increase in the circulating white blood cells 
might be responsible for the alterations of the 
neutrophil, lymphocyte, and monocyte 
proportions. As a results, this may be 
associated with the systemic inflammatory 
response. Therefore, the relationships between 
cancer prognoses and the absolute monocyte 
count, absolute lymphocyte count, neutrophil-
to-lymphocyte ratio (NLR), platelet-to-
lymphocyte ratio (PLR), and lymphocyte-to-
monocyte ratio (LMR) have been evaluated in 
various types of cancer [15–17]. Moreover, the 
chronic systemic inflammatory response has 
been evaluated in terms of the progression and 
prognosis of lung, breast, liver, and pancreatic 
cancers [3,5,16,18,19]. 
In the present study, it was aimed to investigate 
the use of the NLR, PLR, and LMR as systemic 
inflammatory response biomarkers for the 
diagnosis of solid tumors with the goal of using 
laboratory tests more effectively in these 
cancer types. The results of our study will be 
important in terms of the clinical relevancy of 
these new peripheral blood parameter indices. 
 
Methods  
We retrospectively analyzed the records of 
patients with lung, breast, liver, and pancreatic 
cancer solid tumors, who were diagnosed at the 
outpatient clinics of our institution between 
January 2017 and July 2018, following an 
approval from the institutional ethics board 
(2018/224). Those patients without detailed 
laboratory data were excluded from the 
research. In total, 256 patients were enrolled in 
the present study. Additionally, 132 control 
subjects, who were healthy individuals 
presenting for routine check-ups at our 
institution, were enrolled. Each participant’s 
clinical data, including their age, sex, and first 
laboratory results after the cancer diagnosis (in 
the cancer patient group), was obtained from 
their medical records. Those patients who were 
with infectious diseases and hematological 
malignancies, who were suspected of having 
an infection and who had inconsistent 
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information were excluded. The neutrophil, 
lymphocyte, monocyte, and platelet counts 
were measured using a CELL-DYN 3700 
hematology analyzer (Abbott Diagnostics, 
Abbott Park, Illinois, USA). 
Statistical analysis 
The statistical analyses were performed using 
IBM SPSS for Windows version 21 (IBM 
Corp., Armonk, NY, USA). Descriptive 
statistics were used to summarize the patient 
demographics and biomarkers. The continuous 
variables were presented as the mean, standard 
deviation, median, and minimum–maximum. 
Moreover, the categorical variables were 
presented as the frequency and percentage. The 
chi-squared test, independent samples t-test, 
and Mann-Whitney U test were used to 
evaluate the categorical, normal, and skewed 
continuous variables, respectively. A receiver 
operating characteristic (ROC) analysis was 
used to evaluate the performances of the 
biomarkers in discriminating the cases from 
the controls. The significance level was 
considered as 0.05 for all of the analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
In this retrospective study, 388 subjects were 
analyzed: 65.9% were cases and 34.1% were 
control subjects. The distribution of genders 
within the groups were similar to each other 
(Pearson chi-squared analysis, p = 0.784). The 
female percentages in the patient and control 
groups were 51.6% and 53.0%, respectively. 
The results of the comparisons of the ages and 
biomarkers between the case and control 
groups are shown in Table 1. The mean age 
was similar between the cases and controls (p 
=0,390). Although the platelet, lymphocyte, 
and monocyte values were not significantly 
different between the cases and controls, there 
was a significant difference in the NLRs and 
LMRs (p=0.017 and p=0.002). In the patient 
group, the mean NLR value was higher, 
however, the mean LMR value was lower. 
Moreover, the mean PLR value was similar 
between the groups (p = 0.148). 
Table 2 shows the results of the ROC analysis 
used    to     measure   the   performance       of  
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biomarkers in differentiating the cases from 
the controls. The ROC analysis results showed 
that the NLR and LMR were significant 
biomarkers with area under the curve (AUC) 
values of 0.574 (p = 0.017) and 0.596 (p = 
0.002). However, the PLR was not a 
significant biomarker for discriminating the 
cases from the controls (p = 0.148). Figure 1 
shows the ROC curves of the biomarkers. 
Based on the results, the LMR curve was 
below the reference line because the lower 
LMRs indicated disease states. Therefore, we 
subtracted the estimated LMR AUC value 
from one in order to obtain the true AUC value 
in those cases in which the lower values 
indicated the disease. 
 
Tablo 2. ROC analysis results for biomarkers. 
 
ROC: Receiver operating characteristic 
analysis, AUC: Area under the curve values, 
NLR: Neutrophil-to-lymphocyte ratio, LMR: 
Lymphocyte-to-monocyte ratio, PLR: Platelet-
to-lymphocyte ratio.  
 
Discussion 
Because cancer is one of the leading causes of 
mortality, a prompt diagnostic evaluation is 
vital when cancer is suspected. The systemic 
inflammatory response values could represent 
new biomarkers for a cancer diagnosis. The 
systemic inflammatory response is a complex 
reaction involving changes in the protein and 
energy metabolism, hematopoietic systems 
(including the neutrophils, macrophages, and  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. ROC Curves for selected biomarkers. 
 
platelets), and acute phase proteins (including 
the albumin and C-reactive protein, that 
albumin is a negative acute phase reactant). 
Previous studies have shown that the systemic 
inflammatory response biomarkers play 
important roles in the preoperative clinical 
evaluation of patients with solid tumors 
[2,20,21]. Therefore, we investigated the 
diagnostic values of the NLR, PLR, and LMR 
in lung, liver, breast, and pancreatic solid 
tumor cancer cases. Our results showed that 
the NLR and LMR can be used as a reliable 
diagnostic biomarkers. 
In their study of 442 patients diagnosed with 
primary breast cancer, Noh et al. reported that 
the pretreatment with NLR had prognostic 
value in breast cancer cases with regard to the 
disease-specific survival rate and the intrinsic 
subtype [22]. Gomez et al. also evaluated the 
preoperative NLR in hepatocellular carcinoma 
cases, and they reported that, along with the 
hepatic margin involvement, the NLR was an 
independent predictor of a poorer cancer-
specific survival rate [23]. In the current study, 
there was a significant difference between the 
two groups with regard to the NLR (Table 1). 
Moreover, the results of our ROC analysis of 
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the discrimination performance showed that 
the NLR was a significant biomarker with an 
AUC value of 0.574 (p = 0.017). However, this 
value displayed a weak performance. 
Zhang et al. reported that the preoperative PLR 
and NLR had prognostic value in 400 lung 
cancer patients [24]. In their study of 110 
patients, who underwent potentially curative 
resections for pancreatic head cancer, Smith et 
al. reported that the preoperative PLR had 
prognostic value regardless of the tumor size 
and lymph node ratio [25]. In our study, there 
was not any statistically significant difference 
between the two groups with regard to the PLR 
(Table 1). Moreover, the results of the ROC 
analysis of the differentiation performance 
showed that the PLR was not considered a 
reliable biomarker with an AUC value of 0.545 
(p = 0.148). 
In their study of 145 invasive ductal breast 
cancer patients, who underwent surgery, Lee et 
al. reported that the LMR had prognostic value 
with regard to breast cancer [16]. In our study, 
there was a significant difference in the LMRs 
between the two groups (Table 1). Moreover, 
the results of the ROC analysis of the 
differentiation performance showed that the 
LMR was a significant biomarker with an 
AUC value of 0.596 (p = 0.002). However, this 
value did suggest weak performance. 
The abovementioned studies support the 
prognostic and predictive values of the 
preoperative systemic inflammatory response 
biomarker levels. The aim of our study was to 
determine the roles of the systemic 
inflammatory response biomarkers in the 
diagnosis of cancer. However, in cancer cases, 
the systemic inflammatory response may 
simply reflect a nonspecific inflammatory 
response, secondary to tumor hypoxia and 
necrosis or local tissue damage [21]. 
Moreover, the systemic inflammatory 
response may not happen at earlier stages of 
cancer, which may explain the low diagnostic 
value of the biomarkers in the present study. 
The actual mechanism of change of laboratory 
indices in solid tumors is not precise. Elevated 
neutrophils and monocytes values, decreasing 
lymphocyte values are changes showing a 
systemic inflammatory response. These 
changes are thought to be pathologies 
secondary to subclinical inflammation of the 
patients [20]. 
Our study did have several limitations due to 
its retrospective study design. In addition, the 
liver is central to the amplification of the 
systemic inflammatory response. Upon 
stimulation, hepatocytes synthesize and 
release a variety of acute-phase proteins in to 
the systemic circulation that initiate, sustain, or 
curtail the systemic inflammatory response 
[21]. However, the acute-phase proteins, such 
as albumin and the C-reactive protein, were not 
included in our study. Finally, this study 
included a relatively small number of patients. 
Therefore, further prospective studies using 
larger sample sizes are required to verify our 
results. 
Conclusions 
Systemic inflammatory response biomarkers, 
such as the NLR and LMR, can play important 
roles for the clinical diagnosis of patients with 
solid tumors. The techniques used to measure 
these biomarkers are widely available and 
inexpensive; therefore, they can be measured 
routinely in the diagnosis of cancer patients 
with minimal additional costs. 
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